Russell Investments Group Ltd. Purchases 68,493 Shares of Icon Plc $ICLR

Russell Investments Group Ltd. increased its position in shares of Icon Plc (NASDAQ:ICLR) by 38.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 245,647 shares of the medical research company’s stock after purchasing an additional 68,493 shares during the quarter. Russell Investments Group Ltd.’s holdings in Icon were worth $42,988,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Pinnacle Associates Ltd. increased its position in Icon by 25.5% during the 3rd quarter. Pinnacle Associates Ltd. now owns 2,849 shares of the medical research company’s stock worth $499,000 after buying an additional 578 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Icon in the third quarter valued at about $797,000. Vinva Investment Management Ltd bought a new stake in shares of Icon in the third quarter valued at about $332,000. CM Management LLC acquired a new position in shares of Icon in the third quarter valued at about $1,225,000. Finally, Natixis Advisors LLC increased its position in Icon by 4.2% during the third quarter. Natixis Advisors LLC now owns 24,871 shares of the medical research company’s stock worth $4,353,000 after acquiring an additional 1,000 shares during the period. 95.61% of the stock is currently owned by institutional investors.

Icon Trading Down 1.2%

Shares of ICLR opened at $105.38 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. Icon Plc has a 52-week low of $66.57 and a 52-week high of $211.00. The firm has a market cap of $8.51 billion, a price-to-earnings ratio of 14.26, a PEG ratio of 2.73 and a beta of 1.35. The business’s fifty day moving average is $147.59 and its 200-day moving average is $166.49.

Analysts Set New Price Targets

ICLR has been the subject of several analyst reports. Bank of America reiterated an “underperform” rating and issued a $75.00 price objective on shares of Icon in a research note on Thursday, February 12th. Rothschild & Co Redburn set a $100.00 target price on shares of Icon and gave the stock a “neutral” rating in a report on Tuesday, February 17th. Mizuho set a $216.00 price target on shares of Icon in a research report on Friday, January 9th. Truist Financial reiterated a “hold” rating and issued a $222.00 price target (down from $231.00) on shares of Icon in a research note on Thursday, January 8th. Finally, Citigroup reduced their price target on Icon from $200.00 to $120.00 and set a “neutral” rating on the stock in a research report on Wednesday. Six research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Icon currently has an average rating of “Hold” and a consensus target price of $146.80.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.